C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

WATERTOWN, Mass.–(BUSINESS WIRE)–C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively.

Mr. McKee currently also serves as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving the pharmaceutical and biotech industry. Mr. McKee served as Chief Operating Officer and Chief Financial Officer for EKR Therapeutics, Inc. from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. Until March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr from 1996 until its acquisition by Teva. Mr. McKee currently serves on the boards of publicly traded companies including Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.), Agile Therapeutics, Inc. and Aileron Therapeutics, Inc. Mr. (Read more…) McKee received his Bachelor of Business Administration degree from the University of Notre Dame.

Ms. Siegel has nearly 20 years of experience prior to joining C4T. Previously, she served as General Counsel and Secretary at Neon Therapeutics, Inc., or Neon, a publicly-traded immuno-oncology company focused on developing personalized and precision cancer therapies. At Neon, Ms. Siegel was responsible for overseeing all aspects of the legal, intellectual property, compliance and corporate governance functions for the company. In addition, Ms. Siegel contributed to and facilitated key business decisions ranging from data release announcements, equity financing strategy, manufacturing and key vendor relationship management, employee equity and retention matters. She also played a significant role in effecting the sale of Neon to BioNTech SE in May 2020. Prior to Neon, Ms. Siegel served as Senior Vice President, Deputy General Counsel and Assistant Secretary at Intralinks, Inc., a publicly-traded financial technology provider for the global banking, deal making and capital markets communities. Additionally, she was a partner at Choate Hall & Stewart LLP, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies. Earlier in her career, Ms. Siegel was an attorney at Testa, Hurwitz, & Thibeault, LLP. Ms. Siegel received her Juris Doctor from the University of Pennsylvania Law School and her Bachelor of Arts in political science from the University of Pennsylvania, where she graduated cum laude.

“I am thrilled to welcome Bill and Jolie to the C4T team at this exciting time, having recently completed a $170 million dollar financing, a key milestone on our path to becoming a clinical-stage company,” said Marc Cohen, Co-Founder, Chairman and CEO of C4 Therapeutics. “Bill and Jolie’s experience and expertise will be invaluable as we continue to scale our business to rapidly advance our pioneering protein degradation therapeutics to patients suffering from life-threatening diseases.”

“C4T is a transformative company that has attracted a stellar group of investors and pharmaceutical partners to its novel therapeutic approach and TORPEDO discovery platform,” commented Mr. McKee. “I am looking forward to working with the C4T team at this pivotal time in the company’s development.”

“C4T is pioneering a completely novel platform targeting previously elusive drug targets and offers a new approach to treating diseases,” said Ms. Siegel. “I am excited to be a part of this dynamic team as we work together to advance C4T’s drug pipeline into the clinic.”

About C4 Therapeutics

C4 Therapeutics (C4T) is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.

Contacts

Caroline Rufo, Ph.D.

MacDougall

781-235-3060

[email protected]